Sermorelin vs Tesamorelin vs Ipamorelin: Which GH Peptide?

Sermorelin, tesamorelin, and ipamorelin get sold as interchangeable "growth hormone peptides," and clinics often let you pick between them as if you were choosing a flavor. They are not interchangeable. They differ in the receptor they hit, their regulatory status, and — most importantly — the amount and quality of human evidence behind them. That last difference is the one that should drive any honest comparison, because on evidence the three are not even close. This guide lines them up on what actually matters.

The one-line version

Tesamorelin is the only one of the three with modern, RCT-grade outcome data — and it's FDA-approved for a narrow use. Sermorelin and ipamorelin are both compounded, off-label peptides supported mainly by short-term hormone-marker studies and mechanism, not by trials showing they change how people look, feel, or perform. If you remember nothing else: "which GH peptide" is really "one approved drug with real trials versus two plausible-but-unproven compounded peptides."

Different receptors: two are GHRH analogs, one is a ghrelin mimetic

The first real distinction is mechanical. Sermorelin and tesamorelin are both GHRH analogs — they bind the growth-hormone-releasing-hormone receptor on the pituitary to trigger a pulse of your own GH. Sermorelin is GHRH(1-29), the shortest active fragment of GHRH¹; tesamorelin is a stabilized analog of the full GHRH(1-44) peptide built to last longer in the blood².

Ipamorelin is different. It doesn't touch the GHRH receptor at all — it's a selective growth-hormone secretagogue that works through the ghrelin receptor (the same receptor the "hunger hormone" uses), a separate pathway to GH release³. That's why ipamorelin is often combined with a GHRH peptide rather than compared head-to-head: the two pathways can stimulate GH release through different doors, and in animal work a GHRH analog and a ghrelin-type secretagogue given together produced more GH release than either alone⁴. We unpack that pairing logic in the sermorelin + ipamorelin stack and the head-to-head in sermorelin vs ipamorelin.

All three share one upstream feature worth crediting: because they prompt your own pituitary to release GH in pulses rather than injecting GH directly, they preserve the body's natural pulsatile pattern, which is how the GH axis is built to signal⁵. That's a genuine pharmacological point in the class's favor — but preserving pulsatility is a mechanism, not a proven outcome, and the three diverge sharply once you ask what they've actually been shown to do.

The evidence gap is the whole story

This is where any honest comparison has to spend its time.

Tesamorelin has a modern, randomized-controlled-trial base. In its phase 3 program it significantly reduced visceral adipose tissue — the deep abdominal fat around the organs — versus placebo in people with HIV-associated fat accumulation, while raising IGF-1⁶⁷. Randomized data also show it reduces liver fat in HIV-associated fatty liver disease⁸. That earned it an FDA approval, but a narrow one: it's indicated only for excess abdominal fat in HIV-associated lipodystrophy, explicitly not for weight loss, and its long-term cardiovascular safety is not established. Strong evidence, narrow lane. (For the fuller accounting, see tesamorelin benefits and the two-way tesamorelin vs sermorelin.)

Sermorelin's human evidence is older, smaller, and built on surrogate markers. Its best-documented roles are as a diagnostic agent for pituitary GH reserve and a pediatric GH-deficiency treatment¹. The closest adult data is discouraging for the wellness use it's marketed for: nightly GHRH(1-29) injections in healthy older men raised growth hormone but did not significantly raise IGF-1 or change body composition⁹. So sermorelin's anti-aging and body-composition claims are extrapolations from "it raises GH short-term," not proven outcomes — a distinction we hold firm in our pillar evidence guide.

Ipamorelin's human evidence is the thinnest of the three for the uses it's marketed for. It's a well-characterized selective GH secretagogue in preclinical work — meaning it raises GH without spiking cortisol or prolactin the way some older secretagogues did³ — and that selectivity is its real selling point. But there is no body of modern randomized trials showing ipamorelin builds muscle, strips fat, or improves recovery in healthy adults. It's used off-label and compounded, on mechanism and short-term GH data, not outcomes. (Its tolerability profile and what's actually known are in ipamorelin side effects.)

Regulatory status: one approved drug, two compounded peptides

The evidence gap maps onto a regulatory one. Tesamorelin is an FDA-approved finished drug (sold as EGRIFTA SV) with a current label and a defined dose — 2 mg subcutaneously once daily in its approved use⁷. Sermorelin and ipamorelin have no current FDA-approved finished product; sermorelin's old brand (Geref) was discontinued, so both are supplied by compounding pharmacies and prescribed off-label¹. Compounding is legal and routine, but it means potency and purity ride on the pharmacy, and there's no current label or approved indication standing behind the wellness uses. That's a meaningful tier difference when you're deciding what to put in your body.

Shared safety priorities

Because all three drive the GH/IGF-1 axis, they share the same monitoring priorities: a prescriber should track IGF-1 to gauge response and watch glucose, since GH-axis stimulation can affect glucose handling⁵. None is a casual supplement, and anyone with active or hormone-sensitive cancer, or who is pregnant, should not be using GH-axis stimulators off-label — the GH/IGF-1-and-cancer question is serious enough that we treat it separately in does sermorelin cause cancer?. The longer-acting GHRH research peptide CJC-1295 raises related questions about driving the axis harder; we compare it in sermorelin vs CJC-1295.

So which should you consider?

Honestly, the question is usually framed wrong. If you have HIV-associated visceral fat, tesamorelin is the evidence-backed option — but that's a specific medical indication, not a wellness choice, and using it off-label for general fat loss is exactly what its label warns against. For the off-label wellness goals people actually buy these for — sleep, recovery, "optimization," anti-aging — none of the three has modern outcome trials, so the choice between sermorelin and ipamorelin (or a stack of both) comes down to mechanism, tolerability, prescriber preference, and cost, not proven superiority. The most defensible move is to go in clear-eyed: these are plausible nudges to your own GH, not validated body-composition drugs, and they belong under a prescriber who orders baseline and follow-up labs. If you're weighing providers who offer them, we rank them honestly in our guide to the best sermorelin providers.

Bottom line

Three peptides, three different evidence levels. Tesamorelin is the only one with RCT-grade outcome data — and it's approved only for HIV-associated visceral fat, not weight loss. Sermorelin and ipamorelin are compounded, off-label peptides backed by mechanism and short-term hormone markers, with no modern trials proving the body-composition or anti-aging benefits they're marketed for. Compared honestly, it's robust-but-narrow versus plausible-but-unproven (twice over). Pick based on the evidence, not the marketing — and don't let "GH peptide" flatten three very different risk-and-proof profiles into one.